养正消积胶囊联合吉非替尼治疗晚期肺腺癌临床研究  

Clinical research of Yangzheng Xiaoji Capsule Combined with Gefitinib in the Treatment of Advanced Lung Adenocarcinoma

作　　者：李强[1] 唐瑞 吴勇俊 陈玉[1] LI Qiang;TANG Rui;WU Yongjun;CHEN Yu(Traditional Chinese Medicine Hospital of Sichuan Province,Sichuan Chengdu 6011175,China;Chengdu University of Traditional Chinese Medicine,Sichuan Chengdu 6011175,China)

机构地区：[1]四川省中医院肿瘤科,四川成都610075 [2]成都中医大学临床医学院,四川成都610075

出　　处：《中医药临床杂志》2020年第1期108-110,共3页Clinical Journal of Traditional Chinese Medicine

摘　　要：目的:观察养正消积胶囊联合吉非替尼治疗晚期肺腺癌的临床疗效。方法:将63例患者随机分为治疗组(养正消积胶囊联合吉非替尼)32例与对照组(仅使用吉非替尼)31例,并在12周后对治疗组与对照组在肿瘤治疗有效率、不良反应及KPS评分方面进行统计,观察养正消积胶囊的临床疗效。结果:治疗组有效率为71.88%、获益率为90.63%,对照组有效率为35.48%、获益率为83.87%,(P均<0.05);治疗组各不良反应发生的病例数均少于对照组,(P均<0.05);治疗组KPS评分较对照组改善明显,(P<0.05)。结论:养正消积胶囊能提高吉非替尼治疗晚期肺腺癌的临床疗效,并能在减轻不良反应、改善生活质量方面起到辅助作用。Objective:To observe the clinical effect of Yangzheng Xiaoji capsule combined with Gefitinib in the treatment of advanced lung adenocarcinoma.Methods:63 patients were randomly divided into the treatment group (Yangzheng Xiaoji Capsule and Gefitinib) and 32 cases in the control group (only Gefitinib was used).After 12 weeks,the treatment group and the control group were counted in terms of tumor treatment effectiveness,adverse reactions,and KPS scores to observe the clinical efficacy of Yangzheng Xiaoji capsule.Results:The effective rate in the treatment group was 71.88%,and the benefit rate was 90.63%.The effective rate in the control group was 35.48%,and the benefit rate was 83.87% (P<0.05).The number of adverse reactions in the treatment group was less than that in the control group (P<0.05).The KPS score of the treatment group was significantly improved compared with the control group (P<0.05).Conclusion:Yangzheng Xiaoji capsule can improve the clinical efficacy of gefitinib in the treatment of advanced lung adenocarcinoma,and can play an auxiliary role in reducing adverse reactions and improving quality of life.

关 键 词：养正消积胶囊 吉非替尼 晚期肺腺癌 临床疗效 不良反应 生活质量 

分 类 号：R734[医药卫生—肿瘤]